ArticleTranslational cancer research2026
A machine learning-based basement membrane gene signature model for predicting ovarian cancer survival.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer is a highly invasive malignancy that lacks early symptoms. The basement membrane, which separates epithelial and stromal tissues, is highly implicated in tumor development and invasion. Aberrant expression of basement membrane genes is associated with tumor cell infiltration, invasion, and poor prognosis. This study developed a machine learning-based basement membrane gene signature (BMGS) model for predicting the prognosis of patients with ovarian cancer. Methods: Transcriptomic data, clinical data, and the status of 222 basement membrane genes were retrieved from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Genotype-Tissue Expression (GTEx) Project, and basement membraneBASE. After filtering zero-expression genes, we identified differentially expressed genes (P<0.05, and |log2 fold change| >0.585). We selected tumor-related genes, and 7 machine learning algorithms [including extreme gradient boosting (XGBoost)] with 10-fold cross-validation were used to construct the BMGS model, which was validated via Kaplan-Meier curves, receiver operating characteristic (ROC) analysis, and Cox regression. Results: In the multivariate Cox regression analyses, both the TCGA training set (P<0.001) and the GEO validation set (P=0.005) consistently demonstrated that the model was an independent risk factor for ovarian cancer prognosis. The BMGS-high group was associated with significantly higher aneuploidy scores (P<0.001) and higher frequency of Conclusions: This study confirms that the XGBoost-based BMGS with 39 core genes is an independent prognostic factor for ovarian cancer (TCGA: P<0.001; GEO: P=0.005). High BMGS risk correlates with significantly elevated aneuploidy (P<0.001) and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.